Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, Zhang L, Mamedov A, Stanworth SJ, Lin Y. Buckstein R, et al. Among authors: wells ra. Transfusion. 2024 Feb;64(2):223-235. doi: 10.1111/trf.17721. Epub 2024 Feb 7. Transfusion. 2024. PMID: 38323704 Clinical Trial.
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, McQuilten Z, Wood EM, Weinkov R, Zhang L, Mamedov A, Stanworth SJ, Lin Y. Buckstein R, et al. Among authors: wells ra. Am J Hematol. 2024 Mar;99(3):473-476. doi: 10.1002/ajh.27181. Epub 2023 Dec 21. Am J Hematol. 2024. PMID: 38126081 No abstract available.
5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.
Buckstein R, Yee K, Wells RA; Canadian Consortium on Evidence-based Care in MDS. Buckstein R, et al. Among authors: wells ra. Cancer Treat Rev. 2011 Apr;37(2):160-7. doi: 10.1016/j.ctrv.2010.05.006. Epub 2010 Jun 29. Cancer Treat Rev. 2011. PMID: 20591575 Review.
Initial transfusion intensity predicts survival in myelodysplastic syndrome.
Chan LS, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker L, Lee CD, Prica A, Lam A, Mamedov A, Wells RA. Chan LS, et al. Among authors: wells ra. Leuk Lymphoma. 2014 Oct;55(10):2296-300. doi: 10.3109/10428194.2013.878934. Epub 2014 Feb 24. Leuk Lymphoma. 2014. PMID: 24397595
Myelodysplastic syndrome.
Wells RA, Buckstein R, Rezmovitz J. Wells RA, et al. CMAJ. 2016 Jul 12;188(10):751. doi: 10.1503/cmaj.151077. Epub 2016 Jan 4. CMAJ. 2016. PMID: 26728842 Free PMC article. No abstract available.
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM. Buckstein R, et al. Among authors: wells ra. Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033. Epub 2016 Mar 15. Br J Haematol. 2016. PMID: 26991631 Free article. Clinical Trial.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R. Leitch HA, et al. Among authors: wells ra. Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5. Br J Haematol. 2017. PMID: 28677895 Free article.
120 results